ES2279139T3 - Uso de los derivados de epotilona para el tratamiento del hiperparatiroidismo. - Google Patents

Uso de los derivados de epotilona para el tratamiento del hiperparatiroidismo. Download PDF

Info

Publication number
ES2279139T3
ES2279139T3 ES03748446T ES03748446T ES2279139T3 ES 2279139 T3 ES2279139 T3 ES 2279139T3 ES 03748446 T ES03748446 T ES 03748446T ES 03748446 T ES03748446 T ES 03748446T ES 2279139 T3 ES2279139 T3 ES 2279139T3
Authority
ES
Spain
Prior art keywords
parathyroid
treatment
lower alkyl
hydrogen
epothilone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03748446T
Other languages
English (en)
Spanish (es)
Inventor
Eugene A. Woltering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Application granted granted Critical
Publication of ES2279139T3 publication Critical patent/ES2279139T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES03748446T 2002-10-15 2003-10-13 Uso de los derivados de epotilona para el tratamiento del hiperparatiroidismo. Expired - Lifetime ES2279139T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
US418592P 2002-10-15

Publications (1)

Publication Number Publication Date
ES2279139T3 true ES2279139T3 (es) 2007-08-16

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03748446T Expired - Lifetime ES2279139T3 (es) 2002-10-15 2003-10-13 Uso de los derivados de epotilona para el tratamiento del hiperparatiroidismo.

Country Status (15)

Country Link
US (2) US20060142354A1 (https=)
EP (1) EP1553938B1 (https=)
JP (1) JP4672368B2 (https=)
CN (1) CN1297269C (https=)
AT (1) ATE350034T1 (https=)
AU (1) AU2003267751A1 (https=)
BR (1) BR0315293A (https=)
CA (1) CA2501717C (https=)
CY (1) CY1106385T1 (https=)
DE (1) DE60310975T2 (https=)
DK (1) DK1553938T3 (https=)
ES (1) ES2279139T3 (https=)
PT (1) PT1553938E (https=)
SI (1) SI1553938T1 (https=)
WO (1) WO2004035050A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60330407D1 (de) 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1155689B1 (en) * 1993-07-19 2006-09-20 Angiotech Pharmaceuticals, Inc. Anti-angiogenic stents and methods of their preparation
DK1367057T3 (da) * 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
SK287775B6 (sk) * 1998-02-05 2011-09-05 Novartis Ag Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Also Published As

Publication number Publication date
US20110152329A1 (en) 2011-06-23
DE60310975T2 (de) 2007-07-12
BR0315293A (pt) 2005-08-30
EP1553938A1 (en) 2005-07-20
DE60310975D1 (de) 2007-02-15
JP4672368B2 (ja) 2011-04-20
EP1553938B1 (en) 2007-01-03
AU2003267751A1 (en) 2004-05-04
WO2004035050A1 (en) 2004-04-29
CN1703217A (zh) 2005-11-30
DK1553938T3 (da) 2007-03-26
SI1553938T1 (sl) 2007-06-30
CY1106385T1 (el) 2011-10-12
CA2501717C (en) 2012-09-18
CN1297269C (zh) 2007-01-31
JP2006504751A (ja) 2006-02-09
ATE350034T1 (de) 2007-01-15
CA2501717A1 (en) 2004-04-29
US20060142354A1 (en) 2006-06-29
PT1553938E (pt) 2007-03-30
HK1080768A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
US8268837B2 (en) Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
EP0114886B1 (en) Improved analgesic and anti-inflammatory compositions comprising caffeine
CA2440111A1 (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US20090246172A1 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
KR20240104138A (ko) 니로가세스타트를 사용한 조성물 및 치료
JP5642892B2 (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
ES2330324T3 (es) Derivados del epotilon para el tratamiento del hepatoma y de otros canceres.
ES2279139T3 (es) Uso de los derivados de epotilona para el tratamiento del hiperparatiroidismo.
CA2471509A1 (en) Combinations comprising epothilones and anti-metabolites
PT1359905E (pt) Uso de antagonistas de mglur5 para o tratamento de estados pruriginosos
JP2023509191A (ja) 癌を治療するための組み合わせ療法
HK1080768B (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
AU2002366531B2 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
JPH06505740A (ja) 卵巣癌の治療用医薬組成物
JP2004514683A (ja) レバミゾール及び５−フルオロウラシルの同時投与法
HK1069983B (en) Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome
ZA200404013B (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome.
NZ615005B2 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme